New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
